Search results

697 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Public health guidelines Remove Public health guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter

Managing common infections - antimicrobial prescribing guidelines

In development [GID-NG10050] Expected publication date: TBC

Type

NICE guideline

Status

In development
Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

In development [GID-TA10664] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

In development [GID-TA10711] Expected publication date: 15 September 2021

Type

Technology appraisal guidance

Status

In development
Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 06 July 2022

Type

NICE guideline

Status

In development
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

In development [GID-TA10558] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

In development [GID-TA10470] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]

In development [GID-TA10626] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

In development [GID-TA10611] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bulevirtide for treating chronic hepatitis D [ID3732]

In development [GID-TA10652] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

In development
Weight Management

In development [GID-NG10182] Expected publication date: 22 June 2023

Type

NICE guideline

Status

In development
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 27 April 2022

Type

NICE guideline

Status

In development
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Stroke rehabilitation in adults

In development [GID-NG10175] Expected publication date: 14 December 2022

Type

NICE guideline

Status

In development
Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 20 July 2021

Type

NICE guideline

Status

In development
Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10186] Expected publication date: TBC

Type

NICE guideline

Status

In development
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]

In development [GID-TA10538] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 01 September 2021

Type

NICE guideline

Status

In development
Caesarean section (update)

In development [GID-NG10081] Expected publication date: 31 March 2021

Type

NICE guideline

Status

In development
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

In development [GID-NG10173] Expected publication date: TBC

Type

NICE guideline

Status

In development
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]

In development [GID-TA10705] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Nitisinone for treating alkaptonuria [ID2691]

Proposed [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Hypertension in adults: diagnosis and management (update)

In development [GID-NG10177] Expected publication date: 19 April 2023

Type

NICE guideline

Status

In development
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]

In development [GID-TA10766] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862]

In development [GID-TA10744] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

In development [GID-TA10742] Expected publication date: 05 January 2022

Type

Technology appraisal guidance

Status

In development